Pipeline

MIFCOR's suite of ischemia-reperfusion injury-targeting therapies has the potential to be used in many organs and conditions. 

 

Our most advanced clinical candidate, MIF-2, has been studied mechanistically and validated functionally to exert profound protective effects in animal models of cardiac ischemia-reperfusion injury.